Medical Technology and Devices (MTD) Group has completed the acquisition of Ypsomed’s pen needles and blood glucose monitoring (BGM) systems businesses.
Ypsomed’s pen needles operations will be integrated into MTD’s European production and distribution network. This will boost MTD’s total production capacity to over 2.5 billion of pen needles.
Announced initially in late March, the acquisition will help MTD to deliver diabetes and obesity care solutions for both self-care and professional use on an international scale.
For Ypsomed, the deal will enable the company to focus on commercialising and advancing its mylife Loop insulin pump solution.
Ypsomed group diabetes care chief business officer Sébastien Delarive said: “At Ypsomed Diabetes Care, we fully concentrate on innovative insulin pump solutions.”
MTD is a consumer health group with a global portfolio of brands producing diabetes, medical sharps, wound care, heart monitors, thermometers, and nebulisers devices.
The integration of the pen needles and BGM systems businesses is anticipated to bring a range of advanced technologies and trademarks to the consumer health group’s diabetes and obesity portfolio.
Additionally, it will enhance the firm’s current offerings, including the G34, which is claimed to be the thinnest and shortest pen needle available, MTD said.
It will also enable MTD to offer a comprehensive line of pen needles, including options with 3, 5, and 6 bevels.
The group recently launched continuous glucose monitoring systems (CGMs) to enter the Italian market.
MTD’s expanded diabetes care portfolio features products such as the Safety Blood Collection Needle, Vet Catheter, and the new Passive Safety Needle, DropSafe Sicura.
Furthermore, in 2024, MTD introduced new consumer products, including blood pressure monitoring systems (BPMs), nebulisers, footcare items, and insect repellents.
Concurrently, MTD announced an investment plan to develop production facilities for pen needles and lancets in Europe.
These investments are designed to boost capacity and further elevate the performance, quality, and environmental, social, and governance (ESG) standards of the site’s production operations.
MTD CEO Charles Bouaziz said: “By integrating Ypsomed’s Pen Needles and Blood Glucose Monitoring businesses, we solidify our position as a global leader in diabetes care and establish ourselves as the second-largest producer of pen needles worldwide.”
During the transition period, Ypsomed will be manufacturing pen needles as a contract manufacturer and offer support services.
Production equipment will be relocated to MTD sites by mid-2025. The vacated space at Ypsomed’s Solothurn site will be used for new tool-making facilities.
